Conference Reports for NATAP

Back

58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) November 2-6, 2007 Boston, MA     Multiple dose safety and pharmacokinetic study of bavituximab in patients with chronic hepatitis C virus (HCV) infection - (11/30/07)   Decline in the Need for Liver Transplantation for Endstage Liver Disease Secondary to Hepatitis B in the US - (11/26/07)   Higher Caffeine Consumption is associated with Milder Fibrosis in patients with Chronic Liver Diseases - (11/16/07)   Hepatitis D Virus; Triply Infected HIV/HBV/HCV Progress More Quickly - (11/16/07)   Reduction in serum HBsAg level in patients with chronic hepatitis B infected with genotype D induced by (pegylated) interferon alfa-2a alone or in combination with nucleos(t)ide analogs: a long-term single centre cohort study - (11/16/07)   Long-term follow-up of HBsAg clearance in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (PEGASYS): increase in HBsAg clearance rate from 3% 6 months post-treatment to 8% after 3 years - (11/16/07)   An Open Label, Comparative, Multicenter Study Of Peginterferon Alfa-2a Plus Ribavirin In The Treatment Of Patients With Chronic Hepatitis C/Hepatitis B Dual Infection Versus Those With Chronic Hepatitis C Mono-infection - (11/16/07)   Real-Time PCR Quantification of Total Intracellular HBV DNA and cccDNA in HBsAg-Positive Patients with and without HDV co-Infection and in Patients with Occult HBV Infection - (11/16/07)   MAINTENANCE THERAPY FOUND INEFFECTIVE HALT-C STUDY - (11/14/07)   Rapid Virological Response at Week 4 Is the Best Predictor of Treatment Outcome in Patients With Chronic Hepatitis C: A Multivariate Analysis - (11/14/07)   Predictability of Response: Positive and Negative Predictive Values of Rapid and Early Virologic Responses to Peginterferon alfa-2b and Ribavirin in the Treatment of Chronic Hepatitis C - (11/14/07)   Final Results of the Canadian POWeR (Pegetron Prospective Optimal Weight-Based Dosing Response) Program. Sustained Virologic Response (SVR) to Weight-Based Peginterferon alfa-2b + Ribavirin in a Large, Mixed, Community and Academic Observational Study - (11/14/07)   Clinical Relevance of Rapid Virological Response (RVR) in Decompensated HCV-Related Cirrhosis Treated With Peginterferon and Ribavirin - (11/14/07)   Assessment of Virological Response at Week 4 and at Week 12 Optimizes Prediction of Treatment Outcome in Patients With Chronic Hepatitis C Treated With Peginterferon alfa-2b Plus Ribavirin - (11/14/07)   First Multicenter Evaluation of the Efficacy of Tenofovir in Nucleo(t)ide Analog Experienced Patients with HBV Monoinfection - (11/14/07)   Efficacy of Tenofovir DF for the Treatment of Adefovir Resistance - (11/14/07)   Fatty Liver Associated with Metabolics in HBV+ - (11/14/07)   Patients co-infected with HCV and HIV who achieve an RVR (HCV RNA <50 IU/mL at week 4) or cEVR (HCV RNA <50 IU/mL at week 12) have similar rates of SVR to mono-infected patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (11/13/07)   Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) - (11/13/07)   Response-guided therapy in a prospective trial of peginterferon alfa-2a (40KD)/ribavirin treatment in patients with HCV genotype 1 or 4 - (11/13/07)   What is the impact of higher sensitivity assay on response-guided therapy in hepatitis C virus (HCV)? Comparative analysis between COBAS TaqMan™ and COBAS Amplicor™ tests from two large, randomized, international trials of PEGASYS plus COPEGUS - (11/13/07)   Outcomes in HIV-HCV co-infected genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin 1000 or 1200 mg/day: predictions based on generalized additive models - (11/13/07)   Results of a Phase I Placebo-Controlled Trial in Healthy Volunteers to Examine the Safety, Tolerability and PK of the HCV Protease Inhibitor TMC435350 after Single and Repeated Dosing in healthy volunteers - (11/13/07)   In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor TMC435350 - (11/13/07)   Insulin Resistance Predicts HCV Progression in Genotype 1 - (11/13/07)   Pioglitazone Improved Metabolics & Liver Injury in Non-diabetics with NASH - (11/13/07)   Chronic hepatitis C virus infection and risk of hepatocellular carcinoma: a community-based prospective study on 19,565 residents in Taiwan - (11/13/07)   What is the best non invasive method for early prediction of cirrhosis in chronic hepatitis C? Prospective comparison between Fibroscan and serum markers (Lok index, APRI, AST/ALT ratio, platelet count and Fibrotest) - (11/13/07)   HCV patients with genotype 2 or 3 who do not achieve a rapid virologic response (RVR) with peginterferon alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS) are not easy to treat: an analysis of non-RVR patients from the ACCELERATE study - (11/13/07)   High rates of sustained virologic response (SVR) in patients >50 years infected with HCV genotype 1 with positive prognostic factors treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) - (11/13/07)   High chance of cure in HCV genotype 1 patients with a low viral load achieving an RVR treated for 24 weeks with pegylated interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): prospective, randomized, controlled study comparing 24 & 48 weeks of treatment - (11/13/07)   The DIRECT Trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): treatment of non-responders to previous pegylated interferon plus ribavirin: sustained virologic response data - (11/9/07)   Tibotec HCV Protease Inhibitor - (11/9/07)   Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic Hepatitis C patients:Results from a randomized, double-blind, placebo -controlled, ascending multiple dose study - (11/9/07)   Vital Therapies Announces Presentation of ELAD "Artificial Liver" Data at American Association for the Study of Liver Diseases 2007 Annual Meeting - (11/9/07)   Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype 1 infected patients - (11/9/07)   Pegylated interferon alfa-2a (40KD) plus ribavirin (RBV) in prior non-responders to pegylated interferon alfa-2b (12KD)/RBV: final efficacy and safety outcomes of the REPEAT study - (11/8/07)   Rapid and early virological response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study - (11/7/07)   Large Scale Longitudinal Study of Chronic Hepatitis B Patients with Hepatitis B Surface Antigen Seroclearance - (11/7/07)   A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg Positive Chronic Hepatitis B (CHB): Study GS-US-174-0103 - (11/7/07)   A Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg-Negative Chronic Hepatitis B (CHB): Study GS-US-174-0102 - (11/7/07)   Evaluation of Viral Variants During a Phase 2 Study (PROVE2) of Telaprevir with Peg-interferon alfa-2a and Ribavirin in Treatment-naive HCV Genotype 1-Infected Patients - (11/7/07)   Phase 2a study to evaluate the safety and tolerability and anti-viral of 4 doses of a novel, controlled-release interferon-alfa 2b (Locteron) given every 2 weeks for 12 weeks in treatment-naive patients with chronic hepatitis C (genotype 1) - (11/7/07)   Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of R7128, a Novel Nucleoside HCV RNA Polymerase Inhibitor, Following Multiple, Ascending, Oral Doses in Patients with HCV Genotype 1 Infection Who have Failed Prior Interferon Therapy - (11/7/07)   Interim analysis: results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C: Prove 1 - (11/7/07)   A high barrier to resistance may contribute to the robust antiviral effect demonstrated by R1626 in HCV genotype 1-infected treatment-naive patients - (11/7/07)   Robust Synergistic Antiviral Effect of R1626 in Combination with Peginterferon alfa-2a (40KD), with or without Ribavirin, Interim Analysis Results of Phase 2a Study - (11/7/07)   HBV Viral Load Less Than 10,000 copies/mL Is Associated with Significant Risk of Hepatocellular Carcinoma in Chronic Hepatitis B (CHB) Patients: An Update from the R.E.V.E.A.L.-HBV Study - (11/7/07)   Impact of chronically elevated HBV DNA viral load on risk of HCC occurrence: An update from The R.E.V.E.A.L.-HBV Study - (11/7/07)   Changes in Serum HBV DNA Level Using a Trajectory Model to Predict the Risk of HCC in Chronic Hepatitis B Patients: The R.E.V.E.A.L.-HBV Study - (11/7/07)   Gilead's Tenofovir beats Hepsera in second big HBV trial - (11/7/07)   Rapid and early virological response rates are increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety analysis of the induction phase of the CHARIOT study - (11/7/07)   Danazol Increases Platelet Counts in Thrombocytopenia Patients with Chronic Hepatitis C or Cirrhosis - (11/7/07)   Hepatitis C Associated Systemic Cryoglobulinemia: Successful Treatment With Plasma Exchange - (11/7/07)   Long-Term, Low-Dose Treatment With Pegylated Interferon alfa-2b Leads to a Significant Reduction in Fibrosis and Inflammatory Scores in Chronic Hepatitis C Nonresponder Patients With Fibrosis or Cirrhosis - (11/7/07)   Gilead hepatitis C drug may have heart issue-study - (11/5/07)   Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C - (11/5/07)   Four-Year Entecavir Treatment in Nucleoside-Naive, HBeAg(+) Patients: Results from Studies ETV-022 and -901 - (11/5/07)   Long-Term Follow-Up of Entecavir Treated Protocol-Defined 'Non-Responders' in Rollover Study ETV-901 - (11/5/07)   PROVE2: phase II study of telapravir (VX-950) in combination with peginterferon alfa-2 with or without ribavirin in subjects with chronic hepatitis C, an interim analysis - (11/5/07)   Roche's Oral Polymerase Inhibitor Shows Robust Antiviral Efficacy in Treatment of Chronic Hepatitis C - (11/2/07)   Pegasys High Dose Induction for PegIntron Nonresponders: REPEAT Study - (11/2/07)   GILEAD ANNOUNCES 48-WEEK DATA FROM TWO PIVOTAL PHASE III STUDIES EVALUATING VIREAD FOR THE TREATMENT OF CHRONIC HEPATITIS B - (11/2/07)   91% OF BARACLUDE (ENTECAVIR) TREATED PATIENTS IN A FOUR-YEAR COHORT DEMONSTRATED VIROLOGIC SUPPRESSION TO UNDETECTABLE LEVELS - (11/2/07)   Roche Polymerase Inhibitor Shows Promise In Phase II - (11/2/07)   First Studies Demonstrating Greater than 60% Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients (Vertex press release) - (11/2/07)   Phase II Study Shows that Nitazoxanide Significantly Improves Response to Standard of Care in Patients with Chronic Hepatitis C - (11/2/07)   Vertex feeling growing pains Firm scrambles for workers, space as drug shows promise - (11/2/07)   Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C - (11/2/07)   2 New HCV Drugs at AASLD - (11/2/07)